Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 30;9(6):e200109.
doi: 10.1212/NXG.0000000000200109. eCollection 2023 Dec.

Estimated Familial Amyotrophic Lateral Sclerosis Proportion: A Literature Review and Meta-analysis

Affiliations

Estimated Familial Amyotrophic Lateral Sclerosis Proportion: A Literature Review and Meta-analysis

Julie Barberio et al. Neurol Genet. .

Erratum in

Abstract

Background and objectives: Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disorder. Familial (fALS) cases are usually reported to constitute 5%-10% of all ALS cases; however, no recent literature review or meta-analysis of this proportion (referred to throughout as "proportion fALS") has been conducted. Our objective was to estimate the proportion fALS by geographic region and to assess the effect of study characteristics on the estimates.

Methods: A comprehensive literature review was performed to identify all original studies reporting the number of fALS cases in an ALS cohort. The results were stratified by geographic region, study design (case series or population-based), and decade of study publication. Subgroup analyses were conducted according to family history criteria used to define fALS. We report pooled estimates of the proportion fALS from random-effects meta-analyses when >2 studies are available and I2 is < 90%; weighted averages and ranges are otherwise presented.

Results: The overall pooled proportion fALS based on a total 165 studies was 8% (0%, 71%). The proportion fALS was 9% (0%, 71%) among 107 case series and 5% (4%, 6%) among 58 population-based studies. Among population-based studies, proportion fALS by geographic region was 6% (5%, 7%; N = 37) for Europe, 5% (3%, 7%; N = 5) for Latin America, and 5% (4%, 7%; N = 12) for North America. Criteria used to define fALS were reported by 21 population-based studies (36%), and proportion fALS was 5% (4%, 5%; N = 9) for first-degree relative, 7% (4%, 11%; N = 4) for first or second-degree relative, and 11% (N = 1) for more distant ALS family history. Population-based studies published in the 2000s or earlier generated a lower pooled proportion fALS than studies published in the 2010s or later.

Discussion: The results suggest that variability in the reported proportion fALS in the literature may be, in part, due to the differences in geography, study design, fALS definition, and decade of case ascertainment. Few studies outside of European ancestral populations were available. The proportion fALS was marginally higher among case series compared with population-based studies, likely because of referral bias. Criteria used to define fALS were largely unreported. Consensus criteria for fALS and additional population-based studies in non-European ancestral populations are needed.

PubMed Disclaimer

Conflict of interest statement

J. Barberio: employee of Epidemiologic Research & Methods, LLC, doctoral stipend and tuition are supported by an award to Emory University from Amgen Inc; C. Lally: employee of Epidemiologic Research and Methods; V. Kuplian: employee of and holds stock/stock options in Biogen; O. Hardiman: Science Foundation Ireland grants SFI 16/RC/3948 and 20/SP/8953, consulting fees from Cytokinetics, Wave Pharmaceuticals, Orion, Biogen, Denali, Novartis and Accelsior, Editor-in-Chief of the journal ALS and Frontotemporal Degeneration; W.D. Flanders: employee of Epidemiologic Research & Methods, LLC, employee of Rollins School of Public Health. Go to Neurology.org/NG for full disclosures.

References

    1. Brown CA, Lally C, Kupelian V, Flanders WD. Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants. Neuroepidemiology. 2021;55(5):342-353. doi: 10.1159/000516752 - DOI - PubMed
    1. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955. doi: 10.1016/s0140-6736(10)61156-7 - DOI - PubMed
    1. Byrne S, Walsh C, Lynch C, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(6):623-627. doi: 10.1136/jnnp.2010.224501 - DOI - PubMed
    1. Andrew AS, Pioro EP, Li MF, et al. The incidence of amyotrophic lateral sclerosis in Ohio 2016-2018: the Ohio population-based ALS registry. Neuroepidemiology. 2021;55(3):196-205. doi: 10.1159/000515103 - DOI - PMC - PubMed
    1. Marjanović IV, Selak-Djokić B, Perić S, et al. Comparison of the clinical and cognitive features of genetically positive ALS patients from the largest tertiary center in Serbia. J Neurol. 2017;264(6):1091-1098. doi: 10.1007/s00415-017-8495-y - DOI - PubMed